GSK plc (GSK)
After hours:
| Previous close | 40.31 |
| Open | 40.21 |
| Bid | 39.90 x 800 |
| Ask | 40.25 x 3000 |
| Day's range | 39.95 - 40.33 |
| 52-week range | 32.96 - 47.89 |
| Volume | |
| Avg. volume | 5,523,835 |
| Market cap | 81.855B |
| Beta (5Y monthly) | 0.18 |
| PE ratio (TTM) | 14.56 |
| EPS (TTM) | 2.75 |
| Earnings date | 01 Feb 2017 - 06 Feb 2017 |
| Forward dividend & yield | 2.48 (6.16%) |
| Ex-dividend date | 19 May 2022 |
| 1y target est | 56.81 |
- GlobeNewswire
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2
GSK receives exclusive global license option for XMT-2056 Mersana to receive $100 million upfront option purchase feeIf GSK exercises its option, Mersana to receive exercise payment; potential for additional development, regulatory and commercial milestone payments, plus tiered double-digit royalties on net salesMersana to co-develop XMT-2056; retains options for U.S. profit-sharing and U.S. co-promotion Conference call today at 4:30 p.m. ET CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Me
- Business Wire
ADDING MULTIMEDIA GSK and IQVIA launch Vaccine Track, a data trend platform to help improve adult vaccination in communities nationwide
PHILADELPHIA, August 08, 2022--GSK plc (LSE/NYSE: GSK) today announced the launch of Vaccine Track, a comprehensive platform developed by GSK and IQVIA for use by public health officials, industry leaders and medical professionals to strengthen vaccination data transparency, raise awareness and publicly share vaccination trends to aid improvements in routine adult vaccinations to create healthier communities across the US. This resource will provide frequent and relevant data on trends to focus
- Zacks
Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline
Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.
